142 related articles for article (PubMed ID: 36780229)
21. Targeting KRAS
Ciardiello D; Maiorano BA; Martinelli E
ESMO Open; 2023 Feb; 8(1):100745. PubMed ID: 36549128
[TBL] [Abstract][Full Text] [Related]
22. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
23. Discovery of highly potent and selective KRAS
Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S
Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032
[TBL] [Abstract][Full Text] [Related]
24. Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case report.
Bedau T; Heydt C; Siebolts U; Zander T; Kraemer M; Loeser H; Buettner R; Quaas A
Diagn Pathol; 2024 Mar; 19(1):55. PubMed ID: 38539256
[TBL] [Abstract][Full Text] [Related]
25. Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.
Shang Y; Fu S; Hao Q; Ying H; Wang J; Shen T
Bioorg Chem; 2024 Mar; 144():107092. PubMed ID: 38271825
[TBL] [Abstract][Full Text] [Related]
26. KRAS inhibitors: going noncovalent.
Drosten M; Barbacid M
Mol Oncol; 2022 Dec; 16(22):3911-3915. PubMed ID: 36383067
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
[TBL] [Abstract][Full Text] [Related]
28. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
Belli S; Pesapane A; Servetto A; Esposito D; Napolitano F; Ascione CM; Allotta A; Zambrano N; Marino FZ; Franco R; Troiani T; Formisano L; Bianco R
Br J Cancer; 2023 Oct; 129(7):1071-1082. PubMed ID: 37568037
[TBL] [Abstract][Full Text] [Related]
29. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer.
Xiao A; Fakih M
Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38825433
[TBL] [Abstract][Full Text] [Related]
30. KRAS G12C inhibitor combination therapies: current evidence and challenge.
Miyashita H; Kato S; Hong DS
Front Oncol; 2024; 14():1380584. PubMed ID: 38756650
[TBL] [Abstract][Full Text] [Related]
31. Structure-Based Virtual Screening for Novel Inhibitors Targeting KRAS G12C.
Ding Y
Stud Health Technol Inform; 2023 Nov; 308():568-573. PubMed ID: 38007785
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Novel Coumarin-quinolinium Derivatives as Pan-KRAS Translation Inhibitors by Targeting 5'-UTR RNA G-Quadruplexes.
Li ML; Dai LT; Gao ZY; Yan JT; Xu SM; Tan JH; Huang ZS; Chen SB; Chen XC
J Med Chem; 2024 Feb; 67(3):1961-1981. PubMed ID: 38272464
[TBL] [Abstract][Full Text] [Related]
33. Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer.
Bruggemann L; Falls Z; Mangione W; Schwartz SA; Battaglia S; Aalinkeel R; Mahajan SD; Samudrala R
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674513
[TBL] [Abstract][Full Text] [Related]
34. KRAS inhibition in metastatic colorectal cancer: An update.
Nusrat M; Yaeger R
Curr Opin Pharmacol; 2023 Feb; 68():102343. PubMed ID: 36638742
[TBL] [Abstract][Full Text] [Related]
35. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Xue JY; Zhao Y; Aronowitz J; Mai TT; Vides A; Qeriqi B; Kim D; Li C; de Stanchina E; Mazutis L; Risso D; Lito P
Nature; 2020 Jan; 577(7790):421-425. PubMed ID: 31915379
[TBL] [Abstract][Full Text] [Related]
36. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.
Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406
[TBL] [Abstract][Full Text] [Related]
37. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract][Full Text] [Related]
38. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies.
Caughey BA; Strickler JH
Drugs; 2024 Jan; 84(1):27-44. PubMed ID: 38109010
[TBL] [Abstract][Full Text] [Related]
39. 143D, a novel selective KRAS
Xu LS; Zheng SX; Mei LH; Yang KX; Wang YF; Zhou Q; Kong XT; Zheng MY; Jiang HL; Xie CY
Acta Pharmacol Sin; 2023 Jul; 44(7):1475-1486. PubMed ID: 36725884
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer.
Qunaj L; May MS; Neugut AI; Herzberg BO
Front Oncol; 2023; 13():1252516. PubMed ID: 37790760
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]